We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A Merck unit will lose four of its five patents on its skin infection therapy Cubicin after the U.S. Supreme Court denied the drugmaker’s appeal Tuesday. Read More
A new study of oncology approvals shows that a majority of the candidates approved under accelerated review with surrogate endpoints lacked validation. Read More
Industry groups are worried that a section of the proposed FDA and NIH Workforce Authorities Modernization Act would exempt biologics from adhering to U.S. Pharmacopeial standards for quality. Read More
France is tightening restrictions on early-phase clinical trials in the wake of one study that left one patient brain-dead and hospitalized five others. Read More